Oscar Health Inc. (NYSE:OSCR) saw a 12.34% increase in stock price on Friday, nearing its 52-week high, after President Trump decided to postpone a 100% tariff on pharmaceutical imports. This decision provided relief to the company and its insurance counterparts from potentially raising premiums due to high drug costs.

Trump’s decision to delay tariffs on pharmaceutical imports, along with drugmakers’ commitment to invest in US manufacturing, will help lower drug prices over time. This move benefits Oscar Health Inc. (NYSE:OSCR) and allows them to maintain affordable insurance plans for customers amidst potential pricing pressures.

While OSCR shows promise as an investment, some AI stocks may offer higher returns with lower risk. Investors seeking a cheap AI stock benefiting from Trump’s policies can explore further in a free report on the best short-term AI stock. Consider diversifying investments for optimal growth potential.

For more stock recommendations, check out articles on 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Stay informed and make strategic investment decisions to maximize returns in the current market environment.

Read more at Yahoo Finance: Oscar Health (OSCR) Nears 52-Week High on Pharma Tariff Pause